טוען...

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors

BACKGROUND: cKIT kinase overexpression and gain-of-function mutations are the critical pathogenesis of gastrointestinal stromal tumors (GISTs). Although the multiple kinase inhibitors such as imatinib, sunitinib, and regorafenib have been approved for GISTs, the acquisition of polyclonal secondary r...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Ther Adv Med Oncol
Main Authors: Liu, Feiyang, Zou, Fengming, Chen, Cheng, Yu, Kailin, Liu, Xiaochuan, Qi, Shuang, Wu, Jiaxin, Hu, Chen, Hu, Zhenquan, Liu, Juan, Liu, Xuesong, Wang, Li, Ge, Juan, Wang, Wenchao, Ren, Tao, Bai, Mingfeng, Cai, Yujiao, Xiao, Xudong, Qian, Feng, Tang, Jun, Liu, Qingsong, Liu, Jing
פורמט: Artigo
שפה:Inglês
יצא לאור: SAGE Publications 2019
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6535728/
https://ncbi.nlm.nih.gov/pubmed/31205508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919849757
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!